Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib PK in Renal Impairment
NCT04831996Phase 1Completed
- Sponsor
- Incyte
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of parsaclisib in malignancy (5 arms), sponsored by Incyte. Primary endpoints: Maximum Plasma Concentration (Cmax) at 4 Days, Area Under the Curve from Time Zero to Infinity (AUC0-inf) at 4 Days and 1 more. Started May 2021; status: completed.
02
Drugs
parsaclisib
03
Conditions
malignancy
Beyond the preview
Go deeper on NCT04831996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831996.